Alembic Pharmaceuticals Limited has informed the Exchange about Investor Presentation
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals posted Q4 FY25 revenue of INR 17.70 Bn, up 17% year-on-year, driven by strong US Generics (+20% YoY to INR 5.08 Bn) and Ex-US Generics (+43% YoY to INR 3.75 Bn). Full-year FY25 revenue stood at INR 66.72 Bn (+7.1% YoY), with EBIDTA margin improving to 16% from 15% in FY24. Net profit for FY25 was INR 5.84 Bn. India Branded Business grew 8% YoY in Q4 to INR 5.45 Bn, while API revenue declined 9.1% for the full year due to pricing pressure. The company holds 220 cumulative US ANDA approvals with 163 products commercialized and plans 15+ US product launches in FY26. R&D spend was 7.8% of FY25 sales, and ROCE stood at 16%.
Margin expansion, robust US pipeline, and strong Ex-US momentum are positive signals for shareholders. However, the API segment's full-year decline and sustainability of US growth from new facilities remain areas to watch.